Bioxcel

About

We are a biopharmaceutical company pioneering the application of artificial intelligence and big data analytics integrated with drug development expertise. We use our proprietary platforms to advance the next wave of medicines and significantly improve the clinical and regulatory success of drug development.

Our goal is to develop innovative medicines in immuno-oncology, neuroscience, and rare diseases with high unmet need. We believe that our Research & Development Engine can result in a disruptive change that will impact pharma productivity and innovation to benefit the entire healthcare ecosystem.

OUR FAMILY

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company engaged in the development and advancement of the next wave of medicines. The company is focused on a drug re-innovation approach to develop therapeutic candidates with a high probability of clinical and regulatory success.

learn More
OUR FAMILY

InveniAI is pioneering Artificial Intelligence and Big Data driven analytics applications. The company currently offers two groundbreaking artificial intelligence platforms, EvolverAI and PharmGPS® that are applied in drug discovery and development. EvolverAI is used to unearth hidden relationships between diseases, molecular targets and drugs to identify novel therapeutics and re-innovate existing drugs. PharmGPS® is a SAAS platform that is used to project the future performance trajectories of drugs in development

learn More
OUR FAMILY

E.Z. BioXcel, Center of Excellence (CoE) for Research and Development is an innovation hub focused on the development of transformative patient treatments. It houses a rich and diverse cross-functional mix of highly qualified scientific, commercial and medical experts to ensure our partners are able to innovate in an evolving healthcare environment. The center encompasses 100+ years of cumulative drug discovery, development, and management experience in over 100+ indications.

Pipeline

We are leveraging our artificial intelligence and big data capabilites to develop a pipeline of product candidates with a high probability of success in immuno-oncology, neurosciences, and rare diseases.

Therapeutic Area COMPOUND INDICATION Preclinical Phase I Phase II
Immuno-Oncology BXCL701 Solid Tumors
  BXCL702 Hematological malignancies
Neuroscience BXCL501 Acute Agitation
Neuro-oncology BXCL101 NF2
Orphan & Rare Diseases BXCL901 Hematology Diamond Blackfan Anemia
  BXCL902 Neuroscience – Rett Syndrome
  BXCL903 Neuroscience – SCA3 (Spino-Cerebellar Ataxia 3)
  BXCL904 Neuroscience – Krabbe disease

Our Focus

Therapeutic Areas

BioXcel has a special interest in the following disease categories, where we have deep in-house expertise:

  • Immuno-Oncology
    Revolutionizing Cancer Treatments
  • NEUROSCIENCE
    Improving the Quality of Life (QoL) of patients with Neurological Disorders

Rare Diseases

  • Neuroscience
    Improving the Quality of Life of Patients with Rare Neurological Disorders
  • Hematology
    A promising therapy for Rare Hematological Disorder-Diamond Blackfan Anaemia (DBA)
  • Neuro-oncology- NF2
    Innovation in the treatment of Neurofibromatosis type 2 (NF2) tumors

LEADERSHIP

  • VIMAL MEHTA, PH.D. CEO & Chairman
  • KRISHNAN NANDABALAN, PH.D. President & Chief Scientific Officer
  • FRANK D. YOCCA, PH.D. Senior VP, CNS R&D
  • LUCA RASTELLI, PH.D. VP, Oncology R&D
  • CHIDS MAHADEVAN VP, Finance & Chief Accounting Officer
  • ANKUSH SETHI Managing Director, India Operations
  • AMAN KANT VP, Global Head Of Sales & Marketing
  • VIMAL MEHTA, PH.D. CEO & Chairman
  • DEMETRIOS KYDONIEUS R-Pharm U.S.
  • Eric K. Rowinsky Rgenix
  • KRISHNAN NANDABALAN, PH.D. President & Chief Scientific Officer
  • Peter Mueller, Ph.D. Chairman, Scientific Advisory Board
  • SANDEEP “STEVE” LAUMAS, M.D. Bearing Circle Capital
  • Peter Mueller, Ph.D. Chairman, Scientific Advisory Board

Our Partners

BioXcel’s partnerships are focused on the discovery and ideation of innovative drug candidates with a risk mitigated profile and improved probability of clinical and commercial success. Our partnerships are focused on de-novo drug discovery, drug re-innovation, asset rescue, indication expansion, life-cycle management, and product reformulation opportunities.

NEWS

  • Companies are beginning to tap big data to speed drug discovery

    By Peter Winter | BioWorld Insight Editor CBiotechnology is no stranger to the creation and analysis of large amounts of data, whether it is "-omics" in nature or from patients in clinical trials. However, having access to masses of datasets... Read More

  • Cellular Horizons Third International Conference – A New Paradigm in Drug Discovery & Health Care Delivery, Dr. Krishnan Nandabalan, Ph.D., President and CSO, Panel Member

    https://www.youtube.com/watch?v=QDaLoFqPesw Read More

  • Krishnan Nandabalan, President & CSO Discusses the Practical Side of Lab Research

    Read More

  • Silicon India recognises pharma and life sciences solution providers

    (more…) Read More

  • Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim

    BALTIMORE--(BUSINESS WIRE)-- Centrexion Therapeutics, a company focused on advancing chronic pain treatment with new non-opioid and non-surgical therapies, today announced the expansion of its proprietary pipeline with the acquisition of three new analgesic candidates from Boehringer Ingelheim. The company’s proprietary... Read More

  • Cancer Research May Benefit from Big Data Immuno-Oncology Platform

      BioXcel Corporation has announced the launch of its first-in-class PharmGPS Oncology and Immuno-Oncology Suite, which uses big data technology to help biopharmaceutical companies and other stakeholders identify and prioritize the those immunotherapy candidates in their portfolios with the best... Read More

  • Takeda, BioXcel Partner to Repurpose Compounds for Rare Diseases

    BioXcel said today it has joined with Takeda Pharmaceutical’s U.S.-based global development group to repurpose compounds into new treatments for rare diseases. The value of the partnership was not disclosed. BioXcel said the expertise of its Big Data Innovation Lab... Read More

  • Q&A With the President of BioXcel—Makers of Orphan Drug Suite

    http://www.raredr.com/articles/Q-A-BioXcel-Orphan-Drug-Suite Bioxcel’s popularity grew exponentially following the recent news that Alexion Pharmaceuticals is using their platform “Orphan Drug Suite” to assist the orphan drug company in developing and/or discovering new treatments. In this exclusive interview with Rare Disease Report (RDR),... Read More

  • Alexion enlists BioXcel for data dive in search of next Soliris

    FierceBiotechIT January 30, 2015 | By Nick Paul Taylor Alexion Pharmaceuticals ($ALXN) has turned to Big Data specialist BioXcel for help identifying its next blockbuster rare disease drug. BioXcel is applying its rare disease database to the collaboration, which aims... Read More

  • Vimal Mehta, CEO and Chairman interviewed by Equities.com

    This video interview may include forward-looking statements that involve risks and uncertainties. Forward- looking statements are statements that are not historical facts and are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements.... Read More

  • Companies are beginning to tap big data to speed drug discovery

    Biotechnology is no stranger to the creation and analysis of large amounts of data, whether it is "-omics" in nature or from patients in clinical trials. However, having access to masses of datasets is only a good starting point; sooner... Read More